Calcium channel blockers in cardiac failure.
Congestive cardiac failure is an increasingly prevalent syndrome associated with a high morbidity and mortality. The role of calcium channel blockers in the treatment of heart failure is unclear. The potential benefits of these agents derive not only from their vasodilator properties, but also from anti-ischemic effects, beneficial effects on endothelial function and the development of atherosclerosis, and favorable effects on calcium cycling at a molecular level. Pitted against this array of potential benefits are direct negative inotropic effects and the potential for neuroendocrine activation. Treatment with short-acting dihydropyridine agents has not resulted in long-term clinical benefits in patients with cardiac failure. Diltiazem may be beneficial in patients with nonischemic heart failure, and verapamil has a neutral effect in cardiac failure, although it may have a role in combination with ace inhibition. To date, amlodipine has been associated with the most promising results, with evidence of a mortality benefit in nonischemic heart failure. Mibefradil is of no benefit in the management of heart failure, although the trend toward increased mortality in the treatment arm of the Mortality Assessment in Congestive Heart Failure (MACH)-1 trial may have been due to drug interactions. The potential role of calcium blockers in diastolic dysfunction and in combination with ace-inhibition requires further study.
Mahon
N
N
Department of Cardiological Sciences, St George's Hospital Medical School, London, UK.
McKenna
W J
WJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015220:Calcium Channels / Q000737:chemistry / Q000145:classification / Q000378:metabolism; D003971:Diastole / Q000187:drug effects; D004359:Drug Therapy, Combination; D015870:Gene Expression; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009206:Myocardium / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D002118:Calcium